

MOL # 115048

Title Page

Title: Monod-Wyman-Changeux Allosteric Shift Analysis in Mutant $\alpha 1\beta 3\gamma 2L$ GABA_A Receptors Indicates Selectivity and Cross-Talk Among Intersubunit Transmembrane Anesthetic Sites

Authors: Andrea Szabo, Anahita Nourmahnad, Elizabeth Halpin, and Stuart A. Forman

Beecher-Mallinckrodt Laboratories, Department of Anesthesia Critical Care & Pain Medicine,
Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114

MOL # 115048

Running Title Page

Running Title: Crosstalk Among Anesthetic Sites in $\alpha 1\beta 3\gamma 2L$ GABA_A Receptors

Corresponding Author: Stuart A. Forman, MD-PhD

Address correspondence to: Stuart A. Forman, MD-PhD, Dept. of Anesthesia Critical Care & Pain Medicine, Jackson 444, Massachusetts General Hospital, Boston, MA 02114, USA.

Email: saforman@mgh.harvard.edu

Telephone: 617-724-5156

Fax: 617-724-8644

Text pages (excluding title pages, abstract, figure legends, tables, and references): 18

Tables: 3

Figures: 5

References: 40

Word Counts

Abstract: 234

Introduction: 582

Discussion: 1478

Abbreviations: R-mTFD-MPAB = R-5-allyl-1-methyl-5-(m-trifluoromethyl-diazirynylphenyl) barbituric acid.

MOL # 115048

Abstract

Background: Propofol, etomidate, and barbiturate anesthetics are allosteric co-agonists at pentameric $\alpha 1\beta 3\gamma 2$ GABA_A receptors, modulating channel activation *via* four biochemically established inter-subunit transmembrane pockets. Etomidate selectively occupies the two β^+/α^- pockets, the barbiturate photolabel R-mTFD-MPAB occupies homologous α^+/β^- and γ^+/β^- pockets, and propofol occupies all four. Functional studies of mutations at M2-15' or M3-36' loci abutting these pockets provide conflicting results regarding their relative contributions to propofol modulation.

Methods: We electrophysiologically measured GABA-dependent channel activation in $\alpha 1\beta 3\gamma 2$ L or receptors with single M2-15' ($\alpha 1$ S270I, $\beta 3$ N265M, $\gamma 2$ S280W) or M3-36' ($\alpha 1$ A291W, $\beta 3$ M286W, $\gamma 2$ S301W) mutations, in the absence and presence of equi-potent clinical range concentrations of etomidate, R-mTFD-MPAB, and propofol. Estimated open probabilities were calculated and analyzed using global two-state Monod-Wyman-Changeux models to derive $\log(d)$ parameters proportional to anesthetic-induced channel modulating energies.

Results: All mutations reduced $\log(d)$ s for anesthetics occupying both abutting and non-abutting pockets. The $\Delta\log(d)$ s [$\log(d, \text{mut}) - \log(d, \text{wt})$] for M2-15' mutations abutting an anesthetic's biochemically established binding sites were consistently larger than $\Delta\log(d)$ s for non-abutting mutations, although this was not true for M3-36' mutant $\Delta\log(d)$ s. The sums of anesthetic-associated $\Delta\log(d)$ s for sets of M2-15' or M3-36' mutations were all much larger than wild-type $\log(d)$ s.

Conclusions: Mutant $\Delta\log(d)$ s qualitatively reflect anesthetic site occupancy patterns. However, the lack of $\Delta\log(d)$ additivity undermines quantitative comparisons of distinct site contributions to anesthetic modulation, because the mutations impaired both abutting anesthetic binding effects and positive cooperativity between anesthetic binding sites.

MOL # 115048

Introduction

GABA_A receptors are pentameric ligand-gated chloride channels (pLGICs) and major inhibitory neurotransmitter receptors in the mammalian central nervous system (Olsen and Sieghart, 2009; Sigel and Steinmann, 2012). Intravenous general anesthetics including etomidate, propofol, and barbiturates act as allosteric co-agonists at GABA_A receptors, positively modulating GABA activation at low concentrations, and directly activating receptors at high concentrations (Brohan and Goudra, 2017). These actions, assessed electrophysiologically, are quantitatively described by two-state Monod-Wyman-Changeux (MWC) models (Rüsch et al., 2012; Rüsch et al., 2004; Steinbach and Akk, 2019; Ziemba and Forman, 2016).

Genes for 19 different human GABA_A receptor subunits have been identified: α 1-6, β 1-3, γ 1-3, δ , ϵ , π , θ , ρ 1-3 (Olsen and Sieghart, 2009; Sigel and Steinmann, 2012). Each subunit contains a large extracellular domain, a transmembrane domain with four alpha-helices (M1-M4), and an intracellular domain between M3 and M4. Typical synaptic GABA_A receptors contain α , β , and γ subunits arranged β - α - β - α - γ counterclockwise when viewed from the extracellular space, creating four types of subunit interfaces: α^+/β^- , α^+/γ^- , γ^+/β^- and two β^+/α^- (Fig 1) (Baumann et al., 2001; Phulera et al., 2018). Biochemical studies using photolabeling and substituted cysteine modification and protection (SCAMP) have located receptor-bound anesthetics within intersubunit transmembrane pockets between M2 and M3 helices of one subunit ('+' faces) and M1 helices of adjacent subunits ('-' faces) (Forman and Miller, 2016; Nourmahnad et al., 2016). Etomidate and its analogs bind selectively to the two β^+/α^- outer transmembrane interfaces (Li et al., 2006) and the barbiturate photoprobe R-mTFD-MPAB binds selectively in homologous pockets at α^+/β^- and γ^+/β^- interfaces (Chiara et al., 2013). Propofol and its analogs bind within all four pockets that etomidate and R-mTFD-MPAB inhabit, while these and other known anesthetics do not occupy the homologous α^+/γ^- interface (Forman and Miller, 2016; Jayakar et al., 2014; Nourmahnad et al., 2016).

MOL # 115048

The relative contributions of the distinct anesthetic sites to GABA_A receptor gating modulation under drug occupancy conditions associated with general anesthesia remains uncertain. Of particular interest is whether the four sites where propofol binds differentially influence channel function. Conflicting results have emerged from functional studies of receptors with M2-15' or M3-36' mutations (Fig 1) that impair anesthetic modulation (Krasowski et al., 1998; Mihic et al., 1997). Maldifassi et al (2016) compared the effects of M2-15' isoleucine substitutions on propofol modulation at GABA EC₅₀ in $\alpha 1\beta 2\gamma 2L$ receptors, reporting that $\beta 2N265I$ nearly eliminated enhancement, while $\alpha 1S270I$ and $\gamma 2S280I$ respectively produced negligible and small reductions in propofol effects. These results suggest considerable asymmetry in energetic contributions from different propofol binding sites. Subsequently, Shin et al (2018b) used receptors formed from concatenated subunit assemblies and quantitative MWC analysis of currents directly activated by propofol, comparing the effects of $\beta 2M286W$ (M3-36', β^+) and $\beta 2Y143W$ (β^-) mutations individually and in combination. Contrasting with Maldifassi et al, Shin et al reported approximately equal and additive effects of the four mutations, and suggested that up to 6 propofol sites might exist per receptor.

To gain more insight into the relative contributions of different anesthetic sites, we electrophysiologically assessed the effects of single mutations at M2-15' and M3-36' loci in $\alpha 1$, $\beta 3$, and $\gamma 2L$ subunits in wild-type and mutant receptors expressed in *Xenopus* oocytes. We used MWC analysis to quantify shifts in channel gating energy (Feng et al., 2014) induced by equi-effective concentrations of the β^+ site-selective anesthetic etomidate, the β^- site-selective barbiturate R-mTFD-MPAB, and propofol. We also tested whether the combined energy shifts associated with individual subunit mutations at M2-15' or M3-36' accounted for anesthetic effects in wild-type receptors.

MOL # 115048

Materials & Methods

Animals: Female *Xenopus laevis* frogs were used as a source of oocytes for electrophysiology. Frogs were housed in a veterinarian-supervised facility and oocyte harvest procedures were performed with approval from the MGH IACUC, in accordance with state and federal regulations and NIH OACU recommendations.

Materials: DNA sequences encoding human $\alpha 1$, $\beta 3$, and $\gamma 2L$ GABA_A receptor subunits were cloned into pCDNA3.1 plasmids (Thermo Fisher Scientific, USA). Etomidate at 2 mg/ml in sterile 35% propylene glycol:water was purchased from Hospira (Lake Forest, IL, USA). Propofol (2,6-diisopropyl phenol, 99% purity) was purchased from Sigma-Aldrich (St. Louis, MO, USA) and stored as a 100 mM stock in DMSO. R-5-allyl-1-methyl-5-(m-trifluoromethyl-diazirynylphenyl) barbituric acid (R-mTFD-MPAB; 99% pure) was a gift from Prof. Karol Bruzik (Dept. of Medicinal Chemistry and Pharmacognosy, University of Illinois, Chicago, IL) and stored in dark glass containers at -20 °C as a 100 mM stock in DMSO. Anesthetics were diluted into electrophysiology buffer for experiments, with final DMSO < 0.1%. All salts, buffers, and solvents were purchased from Sigma Aldrich and were >98% pure.

Molecular Biology: We studied the effects of previously described mutations at M2-15' and M3-36' positions of $\alpha 1$ ($\alpha 1S270I$ and $\alpha 1A291W$) and $\beta 3$ ($\beta 3N265M$ and $\beta 3M286W$) and tryptophan mutations at the $\gamma 2$ homologs ($\gamma 2S280W$ and $\gamma 2S301W$). We have previously created three of these mutations (Desai et al., 2009; Scheller and Forman, 2002; Stewart et al., 2008).

Oligonucleotide-directed mutagenesis with QuikChange kits (Agilent Technologies, USA) was used to create mutations encoding $\alpha 1A291W$, $\gamma 2S280W$, and $\gamma 2S301W$ in the respective wild-type subunit expression plasmids. The presence of the desired mutations and absence of stray mutations was confirmed by sequencing through the entire cDNA sequence of each mutant plasmid.

Oocyte expression of GABA_A receptors: Ovarian lobes were harvested from female *Xenopus*

MOL # 115048

frogs under tricaine anesthesia. Defolliculated oocytes were prepared as previously described (Stewart et al., 2008). Oocytes were kept in ND-96 (in mM: 96 NaCl, 3 KCl, 1.8 MgCl₂, 1 CaCl₂, 5 HEPES, pH 7.4) at 17 °C. Plasmids encoding wild-type and mutant subunits were linearized and used as templates for in vitro messenger RNA synthesis using commercial kits (Ambion Thermo Fisher, USA). Messenger RNA transcripts were poly-adenylated, purified, and stored in RNAase-free water at -80 °C. Messenger RNA subunit mixtures in ratio 1 α :1 β :5 γ were micro-injected into de-folliculated oocytes (2-10 ng/oocyte).

Oocyte electrophysiology: Oocytes were used in room temperature (20 °C) two-microelectrode voltage-clamp electrophysiology experiments 24 to 96 hours after messenger RNA injection. Oocytes were placed in an open low-volume (30 μ L) flow chamber, and impaled with microelectrodes filled with 3M KCl (< 2 M Ω resistance). Superfusate solutions in ND96 were delivered to the flow-chamber at 2-3 ml/min from glass syringe reservoirs via PTFE tubing and valves and a micro-manifold. Oocytes were voltage-clamped at -50 mV (OC-725C; Warner Instruments, Hamden, CT, USA). Amplified currents were low-pass filtered at 1 kHz, digitized (Digidata 1332; Molecular Devices, San Jose, CA, USA), and recorded at 200 Hz on a computer running ClampEx v8.0 software (Molecular Devices). Current traces were digitally filtered (low-pass 10 Hz) and baseline corrected using ClampFit v8.0 software (Molecular Devices). Spontaneous receptor activity was assessed in each receptor type by measuring picrotoxin (2 mM) inhibition of basal leak currents in the absence of GABA, normalized to maximal GABA (0.1 to 3 mM) currents in the same oocytes (n = 3 oocytes for each receptor type). Maximal GABA efficacy was assessed by comparing maximal currents elicited with GABA alone to currents that were elicited by pre-application (15 to 30s) of 3.2 μ M etomidate, 8 μ M R-mTFD-MPAB, or 5 μ M propofol, followed by maximal GABA plus drug. Using the most effective of the 3 drugs, maximal GABA efficacy was calculated as the ratio of peak current elicited with high GABA alone to the drug-enhanced peak current.

MOL # 115048

GABA-dependent activation of receptors was assessed in the absence and presence of anesthetic solutions that equally modulate $\alpha 1\beta 3\gamma 2L$ receptor gating (approximately 2 x EC50 for LoRR in tadpoles): 3.2 μM etomidate, 8 μM R-mTFD-MPAB, or 5 μM propofol (n = 3 to 5 oocytes per condition). Maximal control currents were assessed frequently (every other or third recording) to correct for variations over time in the number of functional receptors. Currents elicited with GABA (range 0.01 μM to 3 mM) were normalized to the average of preceding and following maximal GABA (0.1 to 3 mM) controls recorded in the same cell. Currents elicited with GABA plus anesthetics (no anesthetic pre-application) were also normalized to currents activated by maximal GABA without anesthetic, in the same cell. If pairs of sequential control currents differed by more than 10%, experiments done between these controls were excluded from analysis.

Estimated P_{open} calculations: Estimated open probability, the fraction of active receptors in an experiment, was calculated from picrotoxin-sensitive basal activity, maximal GABA efficacy, and experimental currents, all normalized to maximal GABA responses (Forman and Stewart, 2011). The calculation assumes that 2 mM picrotoxin inhibits all spontaneously active receptors ($P_{\text{open}} = 0$) and that maximum anesthetic-enhanced high GABA responses represent activation of all functional receptors ($P_{\text{open}} = 1$).

$$P_{\text{open}} = \frac{\frac{I}{I_{\text{GABA}}^{\text{max}}} + \frac{I_{\text{PTX}}}{I_{\text{GABA}}^{\text{max}}}}{\frac{I_{\text{GABA+AN}}}{I_{\text{GABA}}^{\text{max}}} + \frac{I_{\text{PTX}}}{I_{\text{GABA}}^{\text{max}}}} \quad \text{Eq. 1}$$

where I/I_{max} is the normalized experimental current response, $I_{\text{PTX}}/I_{\text{max}}$ is mean normalized spontaneous activity, and $I_{\text{GABA+AN}}/I_{\text{max}}$ is the inverse of mean maximal GABA efficacy.

Descriptive analysis of estimated P_{open} data was performed using non-linear least squares fits to a four-parameter logistic equation (Prism 7, GraphPad, USA):

MOL # 115048

$$P_{\text{open}} = \frac{P_{\text{max}} - P_{\text{min}}}{1 + 10^{(\log EC_{50} - \log [GABA]) \cdot nH}} + P_{\text{min}} \quad \text{Eq. 2}$$

where EC_{50} is the half-activating GABA concentration and nH is the Hill slope.

MWC allosteric shift analyses were performed in Origin 6.1 (OriginLab, Northampton, MA) as global fits to estimated P_{open} data both with and without anesthetic present. We previously described this method to quantify and compare allosteric gating shift factors (d) under identical anesthetic exposure conditions in $\alpha\beta\gamma$ and $\alpha\beta\delta$ GABA_A receptors with dramatically different GABA efficacies (Feng et al., 2014). Here, we modified the approach by fitting $\log(d)$, a value proportional to the anesthetic-induced gating shift free energy, and thus suitable for energy additivity calculations. In these non-linear least-squares fits, equi-effective concentrations of the anesthetics (AN) are treated as a binary factor: 0 if no anesthetic is present, and 1 if present:

$$P_{\text{open}} = \frac{1}{1 + L_0 \times \left(\frac{1 + [GABA]/K_G}{1 + [GABA]/cK_G} \right)^2 \left(\frac{1 + [AN]/10^{-6}}{1 + [AN]/10^{[\log(d)-6]}} \right)} \quad \text{Eq. 3}$$

where L_0 is the basal receptor gating equilibrium (closed:open), K_G is the GABA dissociation constant for closed channels, c is GABA efficacy (ratio of dissociation constants in open/closed states), and $10^{[\log(d)]} = d$ is the allosteric anesthetic shift factor. The model assumes two equivalent GABA sites. When $AN = 0$, the right-hand part of the denominator equals 1 and Eq. 3 simplifies to an MWC equation describing agonism by two equivalent GABA sites:

$$P_{\text{open}} = \frac{1}{1 + L_0 \times \left(\frac{1 + [GABA]/K_G}{1 + [GABA]/cK_G} \right)^2} \quad \text{Eq. 4}$$

When $AN = 1$, Eq. 3 closely approximates:

$$P_{\text{open}} = \frac{1}{1 + L_0 \times 10^{\log(d)} \times \left(\frac{1 + [GABA]/K_G}{1 + [GABA]/cK_G} \right)^2} \quad \text{Eq. 5}$$

$\log(d)$ differences and sums of $\Delta\log(d)$ calculations were performed in Microsoft Excel

MOL # 115048

(Microsoft Corp, Redwood, WA, USA) with propagation of errors (standard deviations) as described by Bevington and Robinson (2002). Wild-type L_0 has been reported over a wide range between 1100 and 70,000 (Chang and Weiss, 1999; Rüsçh et al., 2004; Ziemba and Forman, 2016). Fitted wild-type $\log(d)$ values, and thus calculated $\Delta\log(d)$ s for mutant receptors, were insensitive to fixed wild-type L_0 values between 5000 and 50,000. We chose $L_0 = 5000$ for wild-type fits to Eq. 3. L_0 for $\alpha 1\beta 3N265M\gamma 2L$ receptors was set at twice the wild-type value (10,000), based on previous results (Desai et al., 2009), and L_0 values for other mutants were set based on measured spontaneous open probabilities.

Statistical analyses: The ratios of maximal GABA responses in the presence vs. absence of anesthetic were compared to 1.0 using Student's t-tests. Pairwise comparisons of fitted logistic parameters in the absence and presence of different anesthetics was performed using F-tests in GraphPad Prism 7. For comparisons of $\log(d)$ values among different receptor types and different anesthetics, we calculated t-statistics for the $\log(d)$ differences. $\log(d)$ s and standard errors were derived using 48 or more individual data points fitted to an equation with three free parameters (Eq. 3 with L_0 fixed), indicating at least 45 degrees of freedom, with $t > 2.02$ corresponding to $p < 0.05$. $P < 0.05$ was taken to indicate statistical significance.

MOL # 115048

Results

Receptor Characterization: Spontaneous Gating, GABA EC₅₀, and Maximal GABA efficacy:

We first characterized wild-type $\alpha 1\beta 3\gamma 2L$ and six mutant GABA_A receptors for spontaneous activation and sensitivity to GABA using two-microelectrode voltage clamp electrophysiology (Fig 2, Table 1). Results in wild-type receptors (Table 1) were similar to previous reports (Nourmahnad et al., 2016). In the absence of GABA, we detected no picrotoxin-sensitive current in oocytes expressing $\alpha 1\beta 3\gamma 2L$. Exposure to equi-hypnotic (2 x EC₅₀) anesthetic concentrations (3.2 μM etomidate, 5 μM propofol, or 8 μM mTFD-MPAB) activated wild-type receptors less than 1%. These anesthetic concentrations similarly enhanced maximal (1 to 3 mM) GABA responses by on average 14%, indicating that GABA alone activated approximately 88% of receptors.

All but one of the six mutant receptors conducted picrotoxin-sensitive current in the absence of GABA, indicating spontaneous gating (Fig 2, top panels). No picrotoxin-sensitive currents were observed in oocytes expressing $\alpha 1\beta 3N265M\gamma 2L$ receptors, consistent with previous results (Desai et al., 2009). The other M2-15' mutants, $\alpha 1S270I\beta 3\gamma 2L$ and $\alpha 1\beta 3\gamma 2LS280W$, consistently exhibited small ($\leq 2\%$ of maximal) picrotoxin-inhibited spontaneous currents (Table 1). All three M3-36' mutants displayed over 5% spontaneous activation (Fig 2, Table 1).

Anesthetic enhancement of maximal GABA responses varied among the mutant receptors (Figs 2 and 3). None of the anesthetics enhanced maximal GABA activation of $\alpha 1A291W\beta 3\gamma 2L$ or $\alpha 1\beta 3M286W\gamma 2L$ receptors, indicating GABA efficacies near 100%. Maximal GABA responses in all other mutant receptors were enhanced by at least one of the tested drugs (Fig 2, middle and bottom panels). Current traces recorded for anesthetic enhancement of maximal GABA responses (Fig 2, middle panels) also reveal the effects of anesthetic application alone before adding GABA. With the exception of $\alpha 1\beta 3N265M\gamma 2L$ receptors, the anesthetic that best enhanced GABA responses also directly activated receptors when applied alone.

MOL # 115048

Gating and GABA sensitivity effects of most of the mutations that we studied are consistent with previous reports, most of which used different wild-type backgrounds (Desai et al., 2009; Krasowski et al., 1998; Siegwart et al., 2003; Stewart et al., 2008; Ueno et al., 2000; Ueno et al., 1999). Two M3 mutations, α 1A291W and β 3M286W, display increased spontaneous channel gating, reduced GABA EC₅₀, and increased GABA efficacy (Table 1). These effects are all associated with stabilization of open relative to closed receptors (i.e. decreasing the L₀ parameter in two-state MWC models). Receptors with the M3 mutation γ 2S301W also displayed spontaneous channel activation, but with GABA EC₅₀ and GABA efficacy close to those of wild-type receptors (Table 1), as previously reported (Ueno et al., 1999). Receptors with α 1S270I or γ 2S280W mutations also displayed spontaneous activation together with low GABA efficacy. The α 1S270I receptor reduced GABA EC₅₀ about 10-fold relative to wild-type (Scheller and Forman, 2002; Ueno et al., 1999), while γ 2S280W is characterized by GABA EC₅₀ only 2-fold lower than wild-type. Receptors with β 3N265M mutations exhibited no spontaneous activation and were characterized by reduced GABA efficacy and increased GABA EC₅₀, as previously reported (Desai et al., 2009; Siegwart et al., 2003).

Anesthetic Modulation of GABA-Dependent Receptor Activation

Fig 3 illustrates average GABA concentration-responses, calculated as estimated open probabilities (Eq. 2 in Methods), which includes corrections for spontaneous activation and maximal GABA efficacy (Table 1). The wild-type (α 1 β 3 γ 2L) data demonstrate that all 3 anesthetics, at the equi-hypnotic concentrations used, similarly shifted GABA concentration-responses to lower EC₅₀ and increased maximum GABA efficacy. For the various mutant receptors, the patterns of anesthetic-induced changes in GABA concentration-responses varied, showing different degrees of direct activation (activation at 0 GABA), GABA EC₅₀ shift, and increased GABA efficacy. Parameters from logistic fits to these GABA concentration-responses with and without anesthetics are summarized in Supplemental Table S1.

MOL # 115048

Receptors with $\alpha 1S270I$ or $\alpha 1A291W$ mutations were modulated least by 8 μM R-mTFD-MPAB, and most by 3.2 μM etomidate, while 5 μM propofol produced intermediate effects. In contrast, receptors with either $\beta 3N265M$ or $\beta 3M286W$ mutations were most strongly modulated by R-mTFD-MPAB, but weakly or unaffected by etomidate and propofol. Receptors with $\gamma 2S280W$ or $\gamma 2S301W$ mutations both displayed anesthetic modulation patterns similar to that in $\alpha 1S270I\beta 3\gamma 2L$ receptors. Both mutants were modulated most by etomidate, least by R-mTFD-MPAB, and displayed intermediate sensitivity to propofol.

Some of our observations conflicted with prior reports describing these mutations, perhaps due to different wild-type backgrounds or experimental designs. We observed over 75% reduction of propofol $\log(d)$ in $\alpha 1S270I\beta 3\gamma 2L$ receptors ($p < 0.001$), while Maldifassi et al (2016) reported EC50 modulation in $\alpha 1S270I\beta 2\gamma 2L$ similar to that in wild-type $\alpha 1\beta 2\gamma 2L$. Another earlier study by Krasowski et al (1998) reported moderately less propofol modulation at GABA EC50 in $\alpha 2S270I\beta 1$ receptors than in $\alpha 2\beta 1$. In receptors formed from concatenated subunit assemblies containing two $\beta 2M286W$ mutant subunits, Shin et al (2018b) fitted $L_0 > 10000$, while our experiments revealed 6% spontaneous activity (Table 1), corresponding to $L_0 = 17$ (Table 2), and consistent with our previous results (Stewart et al., 2008). Shin et al also reported that propofol agonist efficacy was reduced less than 50% in the $\beta 2M286W$ double mutant, while we observed that $\beta 3M286W$ mutations nearly obliterated propofol modulation. Krasowski et al (1998) also reported obliteration of propofol modulation in $\alpha 2\beta 1M286W\gamma 2$ receptors, but also reported direct activation by high propofol concentrations. We did not examine the effects of high propofol concentrations in this study.

Allosteric Shift Analyses:

Allosteric two-state equilibrium MWC co-agonist models of anesthetic actions in GABA_A receptors assume the presence of two equivalent GABA sites and account for GABA-dependent activity with three parameters (Eq. 4 in Methods): the basal closed:open gating equilibrium (L_0),

MOL # 115048

the GABA dissociation constant for closed receptors (K_G), and GABA efficacy, the ratio of GABA dissociation constants in open versus closed receptors (c). Anesthetic effects, including receptor activation at zero GABA (direct activation), reductions in GABA EC_{50} , and increased maximal GABA efficacy are all attributed to allosteric co-agonism, which depends on anesthetic concentration, the number of anesthetic sites, and anesthetic affinities for closed versus open receptor states (Rüsch et al., 2012; Rüsch et al., 2004; Steinbach and Akk, 2019). For MWC allosteric shift analyses at equi-effective anesthetic concentrations (established in wild-type receptors), we collapsed all of the above anesthetic factors into a single fitted parameter, $\log(d)$ (Eqs. 3 and 5, Methods). An important advantage of allosteric shift analysis over fitting MWC efficacy from anesthetic-dependent activation is that for receptors with unmeasurable spontaneous activation (e.g. wild-type), $\log(d)$ values are insensitive to L_0 , which is uncertain under these conditions. In our MWC shift analyses, we performed sensitivity tests by constraining L_0 over a range from 50,000 to 5000, resulting in narrow $\log(d)$ parameter ranges for etomidate (-1.92 to -1.96), R-mTFD-MPAB (-2.13 to -2.18), and propofol (-1.89 to -1.95). In contrast, the log of fitted GABA efficacies, $2\log(c)$, in these same calculations ranged from -5.44 to -4.42 as L_0 dropped 10-fold from 50000 to 5000.

Figure 4 illustrates this approach in wild-type $\alpha 1\beta 3\gamma 2L$ and the three M2-15' mutant receptors. Each row of panels illustrates estimated P_{open} results in the absence (black circles) versus presence of a single anesthetic (colored symbols). Both control GABA concentration-responses and the effects of anesthetics were well-fitted ($R^2 > 0.94$) by the MWC allosteric shift equation (Eq. 3 in Methods; solid lines in Fig 4 panels).

Table 2 summarizes the MWC fitted parameters for Fig. 4 and for the MWC fits for M3-36' mutants (not shown). Notably, values for K_G and c varied little among non-linear least-squares fits in the same receptor with different anesthetics, serving as internal consistency checks on the method. The parameters that varied the most among fits for each type of receptor were the

MOL # 115048

log(d)s characterizing the allosteric gating shifts produced by different anesthetics. Fig. 5 illustrates all of the fitted log(d) values for comparison within and between different drugs and receptors.

Mutant-associated log(d) shifts [$\Delta\log(d)$ s, Table 3] are directly proportional to the differences between wild-type and mutant receptors in gating free energy shifts produced by the standardized equi-effective anesthetic concentrations [$\Delta\Delta G = \Delta G(\text{mut}) - \Delta G(\text{wt})$]. We hypothesized that the mutated sites independently and additively contributed to anesthetic modulation, predicting that the sum of $\Delta\log(d)$ s for mutations on all three subunit types would approximately account for wild-type effects (Forman, 2012). However, summing all $\Delta\log(d)$ s for M2-15' or M3-36' mutant effects for each drug resulted in totals that were consistently much larger than the wild-type log(d) values (Table 3; $t > 11$; $p < 0.05$ for both). We reasoned that the mismatch between mutant sums for $\Delta\log(d)$ s and wild-type log(d) might be due to inclusion of both local steric and allosteric effects of mutations in the calculations. Assuming that $\Delta\log(d)$ s for $\alpha+$ and $\gamma+$ mutations with etomidate and $\beta+$ mutations with R-mTFD-MPAB represent purely allosteric effects, we subtracted these from propofol $\Delta\log(d)$ s to estimate residual local mutant effects. However, adjusted sums for both M2-15' and M3-36' mutations still differ from the wild-type log(d) for propofol (Table 3, right column). The sum of adjusted $\Delta\log(d)$ s for the M2-15' mutants, which produced small allosteric effects, exceeded the wild-type log(d) ($t = 6.2$; $p < 0.05$), while that for M3-36' mutants, which produced large allosteric effects, was below the wild-type log(d) ($t = 3.5$; $p < 0.05$).

MOL # 115048

Discussion

We used point mutations and MWC model-based analysis, aiming to quantify the energetic contributions of distinct GABA_A receptor anesthetic sites to channel gating, and to test whether these account for wild-type modulation. Two previous studies used similar approaches, exploiting β^+/α^- interfacial site mutations that reduce anesthetic modulation. Guitchounts et al (2012) used GABA_A receptors formed from concatenated $\beta 1$ - $\alpha 2$ and $\beta 1$ - $\alpha 2$ - $\gamma 2$ assemblies, comparing $\Delta\Delta\log(\text{GABA } EC_{50})$ values for etomidate modulation in wild-type versus receptors with $\alpha 1M236W$ mutant dimers, trimers, or both. The summed energy shifts for dimer and trimer mutants matched the difference between wild-type and double-mutant receptors. More recently, Shin et al (2018b) used MWC analysis of propofol agonism in GABA_A receptors containing one to four propofol site tryptophan mutations. Assuming that each mutation obliterated one site, their results were consistent with independent, additive and approximately equal gating energies per site. Additionally, MWC analyses of wild-type receptor activation with pairs of modulators that act *via* distinct sites provide more evidence of independent and additive energy contributions. (Li et al., 2014; Li et al., 2013; Shin et al., 2018a; Shin et al., 2017) Thus, we hypothesized that independence and additivity is a general feature of anesthetic modulator sites.

Our approach for quantifying mutation-induced changes in anesthetic modulation had several advantages over earlier studies. Using GABA-dependent activation data, MWC shift analysis accounts for anesthetic activation at 0 GABA, reduced GABA EC_{50} , and increased GABA efficacy with a single parameter, $\log(d)$, that is proportional to gating energy change and suitable for additivity tests. This approach is clearly superior to assessing anesthetic effects at a single low GABA concentration (e.g. EC_5). Shifts in $\log(d)$ are also superior to $\Delta\log(\text{GABA } EC_{50})$ calculations, because MWC analyses of P_{open} estimates correct for both spontaneous channel gating (Germann et al., 2018; Stewart et al., 2008) and maximal GABA efficacy in

MOL # 115048

receptor variants (Feng et al., 2014). Our approach is similar in theory to the MWC analysis of direct anesthetic agonism by Shin et al (2018b), but also avoids using high potentially inhibitory drug concentrations. Sensitivity tests also showed that $\log(d)$ is insensitive to the L_0 parameter in wild-type analyses, while MWC efficacy values derived from direct agonism data are strongly dependent on L_0 (Germann et al., 2018).

To evaluate the utility of MWC shift analyses in this study, we used both etomidate, which binds selectively to β^+/α^- transmembrane sites, and R-mTFD-MPAB, which binds selectively to homologous α^+/β^- and γ^+/β^- sites. Previous studies show that $\beta 3N265M$ and $\beta 3M286W$ mutations obliterate etomidate sensitivity (Belelli et al., 1997; Stewart et al., 2008), so we expected mutations in α^+/β^- and γ^+/β^- pockets to minimally affect etomidate modulation. Conversely, we anticipated that $\alpha+$ and $\gamma+$ mutations would impair modulation by R-mTFD-MPAB, while $\beta+$ mutations would produce minimal effects. Indeed, for both etomidate and R-mTFD-MPAB, ranking of $\Delta\log(d)$ values for α , β , and γ mutations at either M2-15' or M3-36' reflects their biochemically established site selectivity (Fig 5, Table 3). Etomidate modulation was affected far less by $\alpha 1$ and $\gamma 2$ mutations than by $\beta 3$ mutations. Correspondingly, R-mTFD-MPAB modulation was reduced far more by $\gamma 2$ and $\alpha 1$ mutations than by $\beta 3$ mutations. Our analysis also suggests that for R-mTFD-MPAB, the γ^+/β^- site mediates a larger effect than the α^+/β^- site, as previously suggested (Chiara et al., 2013; Jayakar et al., 2015). Within subunits, M2-15' mutations consistently impaired modulation more than M3-36' mutations for anesthetics that bind in adjacent sites (Table 3).

For propofol, every mutation reduced $\log(d)$ by at least 50%, with $\Delta\log(d)$ s ranked $\beta 3N265M > \beta 3M286W > \alpha 1S270I \approx \gamma 2S280W > \gamma 2S301W > \alpha 1A291W$ (Fig 5, Table 3). This outcome is consistent with biochemical evidence that propofol binds in all of the sites we studied (Chiara et al., 2013; Jayakar et al., 2014). The larger $\Delta\log(d)$ values for $\beta 3$ mutations probably reflect two β^+/α^- sites per receptor versus the single propofol sites altered by $\alpha 1$ or $\gamma 2$ mutations.

MOL # 115048

However, assuming that each β^+/α^- site contributes half of the propofol $\Delta\log(d)$ associated with $\beta 3N265M$ (Table 3), then each β^+/α^- site contributes less than α^+/β^- or γ^+/β^- sites. Similar analysis for $\beta 3M286W$ suggests that all four propofol sites contribute comparably to channel modulation [$\Delta\log(d)$ range -0.85 to -1.25 per site]. However, we cannot assume that these mutations all completely prevented adjacent anesthetic binding. Analysis of multiple mutations at each position might strengthen such comparisons.

Log(d) analysis (Fig. 5, Table 2) further demonstrated that every mutation reduced the modulating effects of drugs that bind in non-adjacent sites (all at $p < 0.05$). With etomidate, α^+ or γ^+ mutations reduced $\log(d)$ by up to 60% from wild-type. Similarly, $\beta 3$ mutations reduced $\log(d)$ for R-mTFD-MPAB by up to 43%. Interestingly, M3-36' mutations affected non-adjacent anesthetics more than M2-15' mutations in the same subunit. Considering all $\log(d)$ results together with biochemically established site occupation patterns for each drug (Figs 1 and 5) reveals that M2-15' mutations abutting anesthetic sites reduce $\log(d)$ by at least 75% (i.e. $\Delta\log(d) > 1.4$), while non-abutting M2-15' mutations reduce $\log(d)$ by less than 50% (i.e. $\Delta\log(d) < 1.0$). The M3-36' mutant effects do not discriminate as clearly between adjacent and non-adjacent sites. For example, $\gamma 2S301W$ induces $\Delta\log(d) > 1.0$ for etomidate, but is non-abutting, and both $\alpha 1A291W$ and $\gamma 2S301W$ induce $\Delta\log(d) < 1.4$ for propofol.

In contrast to Guitchounts et al (2012) and Shin et al (2018b), we found that the sum of mutant $\Delta\log(d)$ s on all three subunits consistently exceeded $\log(d)$ for wild-type (Table 3). This observation diverges from the expectation that mutant effects in distinct sites are local, independent and energetically additive. Instead, it appears that the mutations also reduced cooperative linkages that reinforce concerted subunit state transitions, which may involve rearrangements of structured water in the anesthetic binding pockets. Alternatively, mutations may have promoted previously unseen inhibitory effects when both etomidate and R-mTFD-MPAB sites are occupied (Jayakar et al., 2015), or even the two R-mTFD-MPAB sites, because

MOL # 115048

each $\alpha+$ or $\gamma+$ mutation reduced $\log(d)$ for the barbiturate by well over 50%. The mutations also could have enhanced anesthetic inhibition, but current traces (e.g. Fig 2, middle panels) showed no relief-of-inhibition “surge” currents.

Most mutations we studied also reduced the MWC efficacy of GABA (inversely proportional to c in Table 2). The exception is $\beta 3N265M$, which also induces no spontaneous activation. This suggests that reduced MWC agonist efficacies, both orthosteric and allosteric, may be associated with spontaneously gating mutant receptors (Germann et al., 2018). However, correcting $\Delta\log(d)$ for $\log(c)$ does not fully reconcile wild-type anesthetic effects with summed mutant shifts (supplemental table S2). Also, M2-L9' mutations are counterexamples in which spontaneous activation is apparently unaccompanied by reduced GABA or anesthetic efficacy in MWC analyses (Chang and Weiss, 1999; Rüsç et al., 2004; Scheller and Forman, 2002).

To summarize, quantitative MWC analyses showed that M2-15' and M3-36' mutations substantially reduce GABA_A receptor modulation by anesthetics that bind in both adjacent and non-adjacent intersubunit pockets. The ranked effects of M2-15' mutations correlated with biochemically established anesthetic site occupancy patterns, validating prior studies (Krasowski et al., 1998; Maldifassi et al., 2016; Mihic et al., 1997; Walters et al., 2000). In comparison, the effects of hydrophobic mutations at M3-36' and on M1 helices (Nourmahnad et al., 2016) don't reliably discriminate between adjacent and non-adjacent anesthetics.

Generalizing from these results, mutant function analyses have limited value for identifying transmembrane drug contact residues, whereas approaches based on covalent modification (e.g. photolabeling or SCAMP) provide strong steric inferences when applicable (Forman, 2018). Surprisingly, previously reported energy additivity among distinct anesthetic sites (Guitchounts et al., 2012; Shin et al., 2018b) is not supported by our current results, complicating quantitative comparisons of different propofol binding sites. Our additivity analysis implies that mutations impaired both adjacent anesthetic binding effects and allosteric cross-talk

MOL # 115048

between sites that underlies cooperativity among anesthetics in wild-type receptors.

Interestingly, previous comparison of the two β^+/α^- sites using $\alpha 1M236W$ mutations in concatenated subunit assemblies (Guitchounts et al., 2012) found equal and additive etomidate effects, while another using $\beta 3N265M$ mutations found unequal etomidate but equal propofol effects (Maldifassi et al., 2016). Thus, different mutations may divergently affect symmetry and/or cross-talk among anesthetic sites. Energy additivity in wild-type GABA_A receptors is supported by studies of drug combinations (Cao et al., 2018; Shin et al., 2017) that notably used receptors formed from concatenated subunit assemblies. Concatenated receptors display less spontaneous activation than free subunit assemblies, and may also reduce heterogeneity in subunit arrangement (Baumann et al., 2001; Guitchounts et al., 2012). Indeed, bulky mutations located at subunit interfaces could disrupt receptor assembly. Studies evaluating the combined energetic effects of etomidate and R-mTFD-MPAB in wild-type GABA_A receptors formed from both free and concatenated subunits are needed for comparison with our current results. Finally, while two-state MWC models of GABA_A receptor function have proven remarkably useful for describing the effects of drugs and mutations, they do not account for multiple closed, open, desensitized, and blocked receptor states that could be differentially affected by these factors.

MOL # 115048

Acknowledgements

R-5-allyl-1-methyl-5-(m-trifluoromethyl-diazirinyphenyl) barbituric acid (R-mTFD-MPAB; 99% pure) was a gift from Prof. Karol Bruzik (Dept. of Medicinal Chemistry and Pharmacognosy, University of Illinois, Chicago, IL). We thank Jonathan B. Cohen (Neurobiology Dept., Harvard Medical School, Boston, MA) for helpful comments on the manuscript.

Authorship Contributions

Participated in research design: Nourmahnad, Szabo, Forman

Conducted experiments: Nourmahnad, Szabo, Halpin

Performed data analysis: Nourmahnad, Szabo, Forman

Wrote or contributed to writing of the manuscript: Forman

MOL # 115048

References

- Baumann SW, Baur R and Sigel E (2001) Subunit arrangement of gamma-aminobutyric acid type A receptors. *J Biol Chem* **276**(39): 36275-36280.
- Belelli D, Lambert JJ, Peters JA, Wafford K and Whiting PJ (1997) The interaction of the general anesthetic etomidate with the gamma-aminobutyric acid type A receptor is influenced by a single amino acid. *Proc Natl Acad Sci U S A* **94**(20): 11031-11036.
- Bevington PR and Robinson DK (2002) *Data Reduction and Error Analysis for the Physical Sciences (3rd Ed.)*. McGraw-Hill, New York, NY.
- Brohan J and Goudra BG (2017) The Role of GABA Receptor Agonists in Anesthesia and Sedation. *CNS Drugs* **31**(10): 845-856.
- Cao LQ, Montana MC, Germann AL, Shin DJ, Chakrabarti S, Mennerick S, Yuede CM, Wozniak DF, Evers AS and Akk G (2018) Enhanced GABAergic actions resulting from the coapplication of the steroid 3alpha-hydroxy-5alpha-pregnane-11,20-dione (alfaxalone) with propofol or diazepam. *Sci Rep* **8**(1): 10341.
- Chang Y and Weiss DS (1999) Allosteric activation mechanism of the alpha1beta2gamma2 gamma-aminobutyric acid type A receptor revealed by mutation of the conserved M2 leucine. *Biophys J* **77**(5): 2542-2551.
- Chiara DC, Jayakar SS, Zhou X, Zhang X, Savechenkov PY, Bruzik KS, Miller KW and Cohen JB (2013) Specificity of intersubunit general anesthetic binding sites in the transmembrane domain of the human alpha1beta3gamma2 GABAA receptor. *J Biol Chem* **288**(27): 19343-19357.
- Desai R, Rüsç D and Forman SA (2009) Gamma-amino butyric acid type A receptor mutations at beta2N265 alter etomidate efficacy while preserving basal and agonist-dependent activity. *Anesthesiology* **111**(4): 774-784.
- Feng HJ, Jounaidi Y, Haburcak M, Yang X and Forman SA (2014) Etomidate Produces Similar Allosteric Modulation in alpha-1/beta-3/delta and alpha-1/beta-3/gamma2L GABA-A Receptors. *Br J Pharmacol* **171**(3): 789-798.
- Forman SA (2012) Monod-Wyman-Changeux allosteric mechanisms of action and the

MOL # 115048

pharmacology of etomidate. *Curr Opin Anaesthesiol* **25**(4): 411-418.

Forman SA (2018) Combining Mutations and Electrophysiology to Map Anesthetic Sites on Ligand-Gated Ion Channels. *Methods Enzymol* **602**: 369-389.

Forman SA and Miller KW (2016) Mapping General Anesthetic Sites in Heteromeric gamma-Aminobutyric Acid Type A Receptors Reveals a Potential For Targeting Receptor Subtypes. *Anesth Analg* **123**(5): 1263-1273.

Forman SA and Stewart D (2011) Mutations in the GABAA receptor that mimic the allosteric ligand etomidate. *Methods in molecular biology (Clifton, NJ)* **796**: 317-333.

Germann AL, Shin DJ, Kuhrau CR, Johnson AD, Evers AS and Akk G (2018) High Constitutive Activity Accounts for the Combination of Enhanced Direct Activation and Reduced Potentiation in Mutated GABAA Receptors. *Mol Pharmacol* **93**(5): 468-476.

Guitchounts G, Stewart DS and Forman SA (2012) The Two Etomidate Sites in alpha1beta2gamma2 gamma-Aminobutyric Acid Type A Receptors Contribute Equally and Noncooperatively to Modulation of Channel Gating. *Anesthesiology* **116**(6): 1235-1244.

Jayakar SS, Zhou X, Chiara DC, Dostalova Z, Savechenkov PY, Bruzik KS, Dailey WP, Miller KW, Eckenhoff RG and Cohen JB (2014) Multiple Propofol Binding Sites in a gamma-Aminobutyric Acid Type A Receptor (GABAAR) Identified Using a Photoreactive Propofol Analog. *J Biol Chem* **289**(40): 456-468.

Jayakar SS, Zhou X, Savechenkov PY, Chiara DC, Desai R, Bruzik KS, Miller KW and Cohen JB (2015) Positive and Negative Allosteric Modulation of an alpha1beta3gamma2 gamma-Aminobutyric Acid Type A (GABAA) Receptor by Binding to a Site in the Transmembrane Domain at the gamma+-beta- Interface. *J Biol Chem* **290**(38): 23432-23446.

Krasowski MD, Koltchine VV, Rick CE, Ye Q, Finn SE and Harrison NL (1998) Propofol and other intravenous anesthetics have sites of action on the gamma-aminobutyric acid type A receptor distinct from that for isoflurane. *Mol Pharmacol* **53**: 530-538.

Li GD, Chiara DC, Sawyer GW, Husain SS, Olsen RW and Cohen JB (2006) Identification of a

MOL # 115048

GABA_A receptor anesthetic binding site at subunit interfaces by photolabeling with an etomidate analog. *J Neurosci* **26**(45): 11599-11605.

Li P, Bracamontes JR, Manion BD, Mennerick S, Steinbach JH, Evers AS and Akk G (2014) The neurosteroid 5beta-pregnan-3alpha-ol-20-one enhances actions of etomidate as a positive allosteric modulator of alpha1beta2gamma2L GABAA receptors. *Br J Pharmacol* **171**(23): 5446-5457.

Li P, Eaton MM, Steinbach JH and Akk G (2013) The benzodiazepine diazepam potentiates responses of alpha1beta2gamma2L gamma-aminobutyric acid type A receptors activated by either gamma-aminobutyric acid or allosteric agonists. *Anesthesiology* **118**(6): 1417-1425.

Maldifassi MC, Baur R and Sigel E (2016) Functional sites involved in modulation of the GABA receptor channel by the intravenous anesthetics propofol, etomidate and pentobarbital. *Neuropharmacology* **105**: 207-214.

Mihic SJ, Ye Q, Wick MJ, Koltchine VV, Krasowski MD, Finn SE, Mascia MP, Valenzuela CF, Hanson KK, Greenblatt EP, Harris RA and Harrison NL (1997) Sites of alcohol and volatile anaesthetic action on GABA(A) and glycine receptors. *Nature* **389**: 385-389.

Nourmahnad A, Stern AT, Hotta M, Stewart DS, Ziemba AM, Szabo A and Forman SA (2016) Tryptophan and Cysteine Mutations in M1 Helices of $\alpha 1\beta 3\gamma 2L$ γ -Aminobutyric Acid Type A Receptors Indicate Distinct Intersubunit Sites for Four Intravenous Anesthetics and One Orphan Site. *Anesthesiology* **125**(6): 1144-1158.

Olsen RW and Sieghart W (2009) GABA(A) receptors: Subtypes provide diversity of function and pharmacology. *Neuropharmacology* **56**: 141-148.

Phulera S, Zhu H, Yu J, Claxton DP, Yoder N, Yoshioka C and Gouaux E (2018) Cryo-EM structure of the benzodiazepine-sensitive alpha1beta1gamma2S tri-heteromeric GABAA receptor in complex with GABA. *Elife* **7**.

Rüsch D, Neumann E, Wulf H and Forman SA (2012) An Allosteric Coagonist Model for Propofol Effects on alpha1beta2gamma2L gamma-Aminobutyric Acid Type A Receptors. *Anesthesiology* **116**(1): 47-55.

MOL # 115048

Rüsch D, Zhong H and Forman SA (2004) Gating allosterism at a single class of etomidate sites on $\alpha 1\beta 2\gamma 2\text{L}$ GABA-A receptors accounts for both direct activation and agonist modulation. *J Biol Chem* **279**(20): 20982-20992.

Scheller M and Forman SA (2002) Coupled and uncoupled gating and desensitization effects by pore domain mutations in GABA(A) receptors. *J Neurosci* **22**(19): 8411-8421.

Shin DJ, Germann AL, Covey DF, Steinbach JH and Akk G (2018a) Analysis of GABAA receptor activation by combinations of agonists acting at the same or distinct binding sites. *Mol Pharmacol*.

Shin DJ, Germann AL, Johnson AD, Forman SA, Steinbach JH and Akk G (2018b) Propofol is an allosteric agonist with multiple binding sites on concatemeric ternary GABAA receptors. *Mol Pharmacol* **93**(2): 178-189.

Shin DJ, Germann AL, Steinbach JH and Akk G (2017) The Actions of Drug Combinations on the GABAA Receptor Manifest as Curvilinear Isoboles of Additivity. *Mol Pharmacol* **92**(5): 556-563.

Sieglwart R, Krahenbuhl K, Lambert S and Rudolph U (2003) Mutational analysis of molecular requirements for the actions of general anaesthetics at the gamma-aminobutyric acidA receptor subtype, $\alpha 1\beta 2\gamma 2$. *BMC pharmacology* **3**: 13.

Sigel E and Steinmann ME (2012) Structure, function, and modulation of GABA(A) receptors. *J Biol Chem* **287**(48): 40224-40231.

Steinbach JH and Akk G (2019) Applying the Monod-Wyman-Changeux Allosteric Activation Model to Pseudo-Steady-State Responses from GABAA Receptors. *Mol Pharmacol* **95**(1): 106-119.

Stewart DS, Desai R, Cheng Q, Liu A and Forman SA (2008) Tryptophan mutations at azido-etomidate photo-incorporation sites on $\alpha 1$ or $\beta 2$ subunits enhance GABAA receptor gating and reduce etomidate modulation *Mol Pharmacol* **74**(6): 1687-1695.

Ueno S, Lin A, Nikolaeva N, Trudell JR, Mihic SJ, Harris RA and Harrison NL (2000) Tryptophan scanning mutagenesis in TM2 of the GABA(A) receptor alpha subunit: effects on channel gating and regulation by ethanol. *Br J Pharmacol* **131**(2): 296-302.

MOL # 115048

Ueno S, Wick MJ, Ye Q, Harrison NL and Harris RA (1999) Subunit mutations affect ethanol actions on GABA(A) receptors expressed in *Xenopus* oocytes. *Br J Pharmacol* **127**: 377-382.

Walters RJ, Hadley SH, Morris KD and Amin J (2000) Benzodiazepines act on GABAA receptors via two distinct and separable mechanisms. *Nature Neuroscience* **3**(12): 1274-1281.

Ziemba AM and Forman SA (2016) Correction for Inhibition Leads to an Allosteric Co-Agonist Model for Pentobarbital Modulation and Activation of alpha1beta3gamma2L GABAA Receptors. *PloS one* **11**(4): e0154031.

MOL # 115048

Footnotes

This work was supported by the National Institutes of Health National Institute of General Medical Sciences [Grant GM089745 to SAF].

MOL # 115048

Legends for Figures

Figure 1: Transmembrane Residues Abutting GABA_A Receptor Anesthetic Sites. The diagram depicts a cross-section of a $\alpha 1\beta 3\gamma 2L$ GABA_A receptor through the transmembrane domain. The arrangement of the five subunits ($\alpha 1$ = yellow; $\beta 3$ = blue; $\gamma 2$ = green) and the relative positions of the transmembrane helices (M1 through M4) is shown. Interfacial aspects of each subunit are labeled '+' (M3 side) or '-' (M1 side). Etomidate or propofol (red and white ovals) occupy the two β^+/α^- interfacial pockets and R-mTFD-MPAB or propofol (dark green and white ovals) occupy the corresponding α^+/β^- and γ^+/β^- pockets. The M1, M2, and M3 contact residues identified in the table below the diagram are depicted as small black circles. None of the three anesthetics bind in the α^+/γ^- interface.

The table below the diagram identifies homologous M1, M2, and M3 residues on each type of subunit that abut inter-subunit anesthetic sites. The effects of mutations at the M1 residues (34 residues before M2-15') have been described previously (Nourmahnad et al., 2016).

Figure 2: Spontaneous Activation and Maximal GABA Efficacy of Mutant GABA_A

Receptors. Top row: Each panel displays current sweeps recorded from a single oocyte expressing $\alpha 1\beta 3\gamma 2L$ receptors containing a single point mutation (labeled above the traces). The purple lines show currents before, during, and after 2 mM picrotoxin (PTX) application, while the black lines show currents activated with maximal GABA (0.3 to 3 mM). Drug applications are indicated by black bars above traces. Outward currents during PTX application represent inhibition of spontaneously active receptors. The PTX traces for $\alpha 1S270I$, $\beta 3N265M$, and $\gamma 2S280W$ have been amplified 10-fold to better illustrate the effects. Average I_{PTX}/I_{GABA} ratios are summarized in table I. **Middle row:** Each panel displays current sweeps recorded from a single oocyte expressing $\alpha 1\beta 3\gamma 2L$ receptors containing a single point mutation (labeled above the traces). The black sweeps show currents activated with maximal GABA. Colored

MOL # 115048

traces are currents recorded during 15 to 30 s pre-exposure to either 3.2 μM etomidate (red lines) or 8 μM R-mTFD-MPAB (green lines) followed by these drugs combined with maximal GABA. Anesthetic applications are indicated by colored bars and GABA applications by black bars above the traces. Note that currents are elicited by anesthetic alone in all but one mutant receptor, and that in four mutant receptors, anesthetic also enhances maximal GABA responses. **Bottom row:** Bars represent normalized ratios (mean \pm SD, $n = 3$) of peak currents in the presence vs. absence of anesthetics (etomidate = red; R-mTFD-MPAB = green; propofol = blue). Increased maximal GABA currents in the presence of anesthetic drugs indicates that GABA alone activates less than 100% of functional receptors (* indicates $p < 0.05$). Maximal GABA efficacy for each mutant receptor is the inverse of the maximum ratio induced by the three drugs (table 1).

Figure 3: Anesthetic Effects on GABA-Dependent Activation of Wild-Type and Mutant GABA_A Receptors. Each panel depicts estimated open probability (mean \pm SEM) calculated (Eq. 1 in methods) from normalized current responses ($n \geq 3$ per condition). Results for GABA alone are shown as solid black circles. Results for GABA plus anesthetic are shown as colored symbols: etomidate = solid red diamonds; R-mTFD-MPAB = solid green triangles; propofol = blue hexagons. Lines through data points represent non-linear least-squares fits to logistic functions (Eq. 2 in methods). Fitted logistic parameters are reported in supplemental table S1.

Figure 4: Anesthetic Induced Monod-Wyman-Changeux Allosteric Shifts in Wild-type and M2-15' Mutant GABA_A Receptors. Each panel displays estimated open probability data points (the same data as in Fig 3) for one type of receptor (identified by labels above columns) and the effects of one equi-effective anesthetic solution (identified by labels to the left of rows). Lines

MOL # 115048

through data points represent non-linear least squares fits to Eq. 3 in Methods with L_0 fixed and 3 free parameters: two that describe GABA responses and one, $\log(d)$, that quantifies anesthetic effects on gating. Lines were plotted using separate equations for GABA alone (Eq. 4 in Methods; black lines) or GABA plus anesthetic (Eq. 5 in Methods; colored lines). The L_0 values and fitted parameters are reported in table 2.

Figure 5: Summary of Anesthetic Allosteric Shift Parameters. Each bar represents a fitted $\log(d)$ value (mean \pm SD) for one of the 3 equi-effective anesthetic solutions in one of the seven types of GABA_A receptors included in this study. Bars are color-coded according to anesthetic (red = 3.2 μ M etomidate; green = 8 μ M R-mTFD-MPAB; blue = 5 μ M propofol) and labeled with the corresponding receptor type. Mutants are grouped into M2-15' and M3-36' subgroups. Asterisks indicate mutations at loci that are adjacent to the anesthetic's binding sites, based on biochemical studies.

MOL # 115048

Table 1
Functional Characteristics of GABA_A Receptor Mutants

Receptor	GABA EC ₅₀ (μM) [95% CI]	GABA Efficacy ± SD	I _{PTX} /I _{GABAmax} ±SD
α1β3γ2L	59 [53 to 66] (n = 3)	0.88 ± 0.024 (n = 5)	< 0.001 (n = 3)
M2-15	α1S270Iβ3γ2L	2.3 [2.1 to 2.6] (n = 3)	0.78 ± 0.054 (n = 6)
	α1β3N265Mγ2L	141 [128 to 156] (n = 3)	0.75 ± 0.024 (n = 4)
	α1β3γ2LS280W	29 [24 to 35] (n = 4)	0.70 ± 0.053 (n = 3)
M3-36	α1A291Wβ3γ2L	0.37 [0.27 to 0.52] (n = 3)	0.99 ± 0.036 (n = 6)
	α1β3M286Wγ2L	5.9 [4.5 to 7.7] (n = 4)	0.96 ± 0.032 (n = 5)
	α1β3γ2LS301W	43 [32 to 58] (n = 3)	0.84 ± 0.054 (n = 7)

Table 2
Fitted Parameters from Monod-Wyman-Changeux Allosteric Shift Analysis

Mutation	L ₀	Etomidate (3.2 μM)			R-mTFD-MPAB (8 μM)			Propofol (5 μM)		
		K _G ± sd (μM)	c ± sd	Log(d) ± sd	K _G ± sd (μM)	c ± sd	Log(d) ± sd	K _G ± sd (μM)	c ± sd	Log(d) ± sd
Wild-Type	5000	90 ± 13	0.0061 ± 0.00040	-1.91 ± 0.075	100 ± 13	0.0059 ± 0.00037	-2.13 ± 0.065	90 ± 11	0.0061 ± 0.00035	-1.89 ± 0.065
α1S270I	60	4.0 ± 0.65	0.064 ± 0.00047	-1.58 ± 0.043	3.1 ± 0.46	0.071 ±0.0043	-0.42 ± 0.036	4.0 ± 0.69	0.065 ± 0.0049	-0.44 ± 0.039
β3N265M	10000	110 ± 10	0.0065 ± 0.00021	-0.024 ± 0.023	90 ± 20	0.0068 ± 0.0041	-1.49 ± 0.078	110 ± 10	0.0066 ± 0.00023	-0.09 ± 0.023
γ2S280W	100	31 ± 4.1	0.068 ± 0.0033	-1.21 ± 0.042	25 ± 4.1	0.070 ± 0.0041	0.16 ± 0.041	18 ± 2.7	0.076 ± 0.0036	-0.39 ± 0.037
α1A291W	10	1.1 ± 0.24	0.09 ± 0.012	-1.22 ± 0.038	1.0 ± 0.35	0.10 ± 0.019	-0.49 ± 0.071	1.3 ± 0.47	0.09 ± 0.019	-0.93 ± 0.055
β3M286W	17	14 ± 4.5	0.08 ± 0.014	-0.22 ± 0.094	18 ± 6.5	0.07 ± 0.016	-1.20 ± 0.045	16 ± 5.1	0.07 ± 0.013	-0.20 ± 0.085
γ2S301W	15	27 ± 7.3	0.14 ± 0.014	-0.72 ± 0.054	43 ± 8.2	0.14 ± 0.010	-0.25 ± 0.053	28 ± 8.3	0.14 ± 0.015	-0.64 ± 0.062

Values were derived from non-linear least squares fits with equation 3 (Methods) with L₀ constrained (3 dependent parameters), to pooled P_{open} estimates. At least 48 P_{open} values from experiments at 8 or more GABA concentrations, with and without anesthetics, in at least 3 different oocytes were used in each calculation. Figure 4 displays both data and fitted models.

MOL # 115048

Table 3
Additivity of $\Delta\text{Log}(d)$ Values for M2 and M3 Mutations by Drug

	Mutations	Etomidate	mTFD-MPAB	Propofol	Propofol (adj) ¹
	Wild-Type	-1.91 ± 0.075	-2.13 ± 0.065	-1.89 ± 0.065	-1.89 ± 0.065
		$\Delta\text{Log}(d)$ (mut – wt) ± sd			
M2-15	α 1S270I	0.33 ± 0.086 *	1.71 ± 0.074	1.45 ± 0.076	1.12 ± 0.11
	β 3N265M	1.89 ± 0.078	0.64 ± 0.10 *	1.81 ± 0.069	1.17 ± 0.12
	γ 2S280W	0.70 ± 0.086 *	2.29 ± 0.077	1.50 ± 0.075	0.80 ± 0.11
	Sum (x -1)	-2.9 ± 0.15	-4.6 ± 0.15	-4.8 ± 0.13	-3.1 ± 0.20
M3-36	α 1A291W	0.69 ± 0.084 *	1.6 ± 0.96	0.96 ± 0.085	0.27 ± 0.12
	β 3M286W	1.7 ± 0.12	0.93 ± 0.079 *	1.7 ± 0.11	0.76 ± 0.13
	γ 2S301W	1.19 ± 0.092 *	1.88 ± 0.084	1.25 ± 0.091	0.06 ± 0.13
	Sum (x -1)	-3.6 ± 0.17	-4.5 ± 0.15	-3.9 ± 0.16	-1.1 ± 0.22

Values for wild-type are $\log(d) \pm \text{sd}$, from fits of Eq. 3 (Methods) to estimated P_{open} data (see Fig. 4 and Table 2). Values for mutant receptors represent differences between $\log(d)$ s for wild-type and mutants. ¹ Adjusted propofol $\Delta\log(d)$ values were calculated by subtracting presumed allosteric mutant effects based on etomidate and R-mTFD-MPAB experiments (identified by an asterisk in each mutant row) from unadjusted propofol $\Delta\log(d)$ s.

MOL # 115048




Figure 1: Transmembrane Residues Abutting GABA_A Receptor Anesthetic Sites. The diagram depicts a cross-section of a $\alpha 1\beta 3\gamma 2$ L GABA_A receptor through the transmembrane domain. The arrangement of the five subunits ($\alpha 1$ = yellow; $\beta 3$ = blue; $\gamma 2$ = green) and the relative positions of the transmembrane helices (M1 through M4) is shown. Interfacial aspects of each subunit are labeled '+' (M3 side) or '-' (M1 side). Etomidate or propofol (red and white ovals) occupy the two β^+/α^- interfacial pockets and R-mTFD-MPAB or propofol (dark green and white ovals) occupy the corresponding α^+/β^- and γ^+/β^- pockets. The M1, M2, and M3 contact residues identified in the table below the diagram are depicted as small black circles. None of the three anesthetics bind in the α^+/γ^- interface.

The table below the diagram identifies homologous M1, M2, and M3 residues on each type of subunit that abut bound inter-subunit anesthetics. The effects of mutations at the M1 residues (34 residues before M2-15') have been described previously (Nourmahnad et al., 2016).

MOL # 115048




Figure 2: Spontaneous Activation and Maximal GABA Efficacy of Mutant GABA_A Receptors.

Top row: Each panel displays current sweeps recorded from a single oocyte expressing $\alpha 1\beta 3\gamma 2L$ receptors containing a single point mutation (labeled above the traces). The purple lines show currents before, during, and after 2 mM picrotoxin (PTX) application, while the black lines show currents activated with maximal GABA (0.3 to 3 mM). Drug applications are indicated by black bars above traces. Outward currents during PTX application represent inhibition of spontaneously active receptors. The PTX traces for $\alpha 1S270I$, $\beta 3N265M$, and $\gamma 2S280W$ have been amplified 10-fold to better illustrate the effects. Average I_{PTX}/I_{GABA} ratios are summarized in table 1. **Middle row:** Each panel displays current sweeps recorded from a single oocyte expressing $\alpha 1\beta 3\gamma 2L$ receptors containing a single point mutation (labeled above the traces). The black sweeps show currents activated with maximal GABA. Colored traces are currents recorded during 15 to 30 s pre-exposure to either 3.2 μM etomidate (red lines) or 8 μM R-mTFD-MPAB (green lines) followed by these drugs combined with maximal GABA. Anesthetic applications are indicated by colored bars and GABA applications by black bars above the traces. Note that currents are elicited by anesthetic alone in all but one mutant receptor, and that in four mutant receptors, anesthetic also enhances maximal GABA responses. **Bottom row:** Bars represent normalized ratios (mean \pm SD, $n = 3$) of peak currents in the presence vs. absence of anesthetics (etomidate = red; R-mTFD-MPAB = green; propofol = blue). Increased maximal GABA currents in the presence of anesthetic drugs indicates that GABA alone activates less than 100% of functional receptors (* indicates $p < 0.05$). Maximal GABA efficacy for each mutant receptor is the inverse of the maximum ratio induced by the three drugs (table 1).

MOL # 115048




Figure 3: Anesthetic Effects on GABA-Dependent Activation of Wild-Type and Mutant $GABA_A$ Receptors. Each panel depicts estimated open probability (mean \pm SEM) calculated (Eq. 1 in methods) from normalized current responses ($n \geq 3$ per condition). Results for GABA alone are shown as solid black circles. Results for GABA plus anesthetic are shown as colored symbols: etomidate = solid red diamonds; R-mTFD-MPAB = solid green triangles; propofol = blue hexagons. Lines through data points represent non-linear least-squares fits to logistic functions (Eq. 2 in methods). Fitted logistic parameters are reported in supplemental table S1.

MOL # 115048




Figure 4: Anesthetic Induced Monod-Wyman-Changeux Allosteric Shifts in Wild-type and M2-15' Mutant GABA_A Receptors. Each panel shows individual estimated open probability data points (the same data as in Fig 3) for one type of receptor (identified by labels above columns) and the effects of one equi-effective anesthetic solution (identified by labels to the left of rows). Lines through data points represent non-linear least squares fits to Eq. 3 in Methods with L_0 fixed and 3 free parameters: two that describe GABA responses and one, $\log(d)$, that quantifies anesthetic effects on gating. Lines were plotted using separate equations for GABA alone (Eq. 4 in Methods; black lines) or GABA plus anesthetic (Eq. 5 in Methods; colored lines). The L_0 values and fitted parameters are reported in table 2.

MOL # 115048




Figure 5: Summary of Anesthetic Allosteric Shift Parameters. Each bar represents a fitted $\log(d)$ value (mean \pm SD) for one of the 3 equi-effective anesthetic solutions in one of the seven types of GABA_A receptors included in this study. Bars are color-coded according to anesthetic (red = 3.2 μM etomidate; green = 8 μM R-mTFD-MPAB; blue = 5 μM propofol) and labeled with the corresponding receptor type. Mutants are grouped into M2-15' and M3-36' subgroups. Asterisks indicate mutations at loci that are adjacent to the anesthetic's binding sites, based on biochemical studies. $\Delta \log(d)$ is calculated as $\log(d, \text{mut}) - \log(d, \text{wt})$.

MOL # 115048

Supplemental Data

**Title: Monod-Wyman-Changeux Allosteric Shift Analysis in Mutant $\alpha 1\beta 3\gamma 2L$ GABA_A Receptors
Indicates Selectivity and Cross-Talk Among Intersubunit Transmembrane Anesthetic Sites**

Authors: Andrea Szabo, Anahita Nourmahnad, Elizabeth Halpin, and Stuart A. Forman

Journal: Molecular Pharmacology

Supplemental Table S1
Non-Linear Least Squares Fitted Logistic Parameters from Figure 3

Receptor (n)	Fitted Parameter	GABA	GABA + ETO	GABA +MPAB	GABA + PRO
$\alpha 1\beta 3\gamma 2L$ (n \geq 3)	P_{min} (SE)	0.00 (0.008)	0.00 (0.010)	0.03 (0.012)	0.01 (0.012)
	P_{max} (SE)	0.87 (0.012)	1.00 (0.014)	0.99 (0.016)	0.98 (0.017)
	EC_{50} (μM) [95% CI]	59 [53 to 66]	4.1 [3.6 to 4.7]	3.3 [2.8 to 3.8]	4.0 [3.5 to 4.7]
	nH (SE)	1.16 (0.062)	1.00 (0.056)	1.10 (0.079)	1.21 (0.092)
$\alpha 1S270I\beta 3\gamma 2L$ (n \geq 3)	P_{min} (SE)	0.020 (0.0089)	0.34 (0.059)	0.061 (0.0097)	0.05 (0.012)
	P_{max} (SE)	0.78 (0.011)	0.96 (0.059)	0.89 (0.011)	0.98 (0.017)
	EC_{50} (μM) [95% CI]	2.3 [2.1 to 2.6]	0.17 [0.06 to 0.45]	1.1 [0.98 to 1.3]	1.8 [1.5 to 2.2]
	nH (SE)	1.5 (0.11)	0.8 (0.30)	0.91 (0.053)	0.77 (0.049)
$\alpha 1\beta 3N265M\gamma 2L$ (n \geq 3)	P_{min} (SE)	0.00 (0.005)	0.00 (0.003)	0.02 (0.010)	0.00 (0.003)
	P_{max} (SE)	0.72 (0.018)	0.73 (0.010)	0.96 (0.013)	0.74 (0.010)
	EC_{50} (μM) [95% CI]	118 [96 to 145]	117 [103 to 132]	11 [10 to 13]	96 [85 to 108]
	nH (SE)	0.99 (0.079)	1.12 (0.062)	1.19 (0.075)	1.14 (0.062)
$\alpha 1\beta 3\gamma 2LS280W$ (n \geq 3)	P_{min} (SE)	0.015 (0.0084)	0.15 (0.016)	0.01 (0.018)	0.014 (0.0073)
	P_{max} (SE)	0.71 (0.017)	1.01 (0.030)	0.74 (0.072)	0.84 (0.015)
	EC_{50} (μM) [95% CI]	29 [24 to 35]	4.9 [3.6 to 6.6]	59 [24 to 144]	8.3 [7.1 to 9.7]
	nH (SE)	0.97 (0.076)	0.9 (0.11)	0.6 (0.10)	0.88 (0.051)
$\alpha 1A291W\beta 3\gamma 2L$ (n \geq 3)	P_{min} (SE)	0.08 (0.032)	0.63 (0.018)	0.28 (0.019)	0.50 (0.035)
	P_{max} (SE)	1.0 (0)	1.01 (0.018)	0.99 (0.016)	1.0 (0.012)
	EC_{50} (μM) [95% CI]	0.37 [0.27 to 0.52]	0.10 [0.06 to 0.17]	0.35 [0.26 to 0.49]	0.25 [0.13 to 0.51]
	nH (SE)	0.84 (0.087)	0.9 (0.15)	0.67 (0.064)	0.8 (0.16)
$\alpha 1\beta 3M286W\gamma 2L$ (n \geq 3)	P_{min} (SE)	0.05 (0.023)	0.07 (0.013)	0.50 (0.018)	0.09 (0.013)
	P_{max} (SE)	1.0 (0)	1.0 (0)	1.0 (0)	1.0 (0)
	EC_{50} (μM) [95% CI]	5.9 [4.5 to 7.7]	4.0 [3.4 to 4.6]	1.7 [1.1 to 2.5]	4.6 [4.1 to 5.3]
	nH (SE)	0.77 (0.063)	0.79 (0.035)	1.0 (0.15)	1.00 (0.050)
$\alpha 1\beta 3\gamma 2LS301W$ (n \geq 3)	P_{min} (SE)	0.05 (0.013)	0.17 (0.013)	0.101 (0.0050)	0.13 (0.010)
	P_{max} (SE)	0.90 (0.029)	0.99 (0.021)	0.88 (0.013)	1.03 (0.019)
	EC_{50} (μM) [95% CI]	43 [32 to 58]	3.0 [2.4 to 3.9]	20 [18 to 23]	4.4 [3.6 to 5.3]
	nH (SE)	0.71 (0.060)	0.81 (0.073)	0.70 (0.028)	0.81 (0.053)

Fits are to Eq. 1 in Methods. ETO = 3.2 μM etomidate; MPAB = 8 μM R-mTFD-MPAB; PRO = 5 μM propofol

Table S2

Additive Allosteric Effects of M2 and M3 Mutations by Drug, Corrected for GABA Efficacy

Mutations	Log(c)	$\Delta[\text{Log}(d)-\text{Log}(c)]$ values \pm sd			
		Etomidate	mTFD-MPAB	Propofol	
Wild-Type	-2.22 \pm 0.0084	0.31 \pm 0.075	0.09 \pm 0.070	0.33 \pm 0.070	
M2-15	α 1S270I	-1.18 \pm 0.024	0.71 \pm 0.090	-0.67 \pm 0.083	-0.41 \pm 0.084
	β 3N265M	-2.18 \pm 0.010	-1.84 \pm 0.080	-0.60 \pm 0.11	-1.76 \pm 0.075
	γ 2S280W	-1.15 \pm 0.025	0.37 \pm 0.090	-1.22 \pm 0.085	-0.43 \pm 0.083
	Sum		-0.8 \pm 0.15	-2.5 \pm 0.16	-2.6 \pm 0.14
M3-36	α 1A291W	-1.03 \pm 0.026	0.50 \pm 0.089	-0.45 \pm 0.10	0.23 \pm 0.093
	β 3M286W	-1.14 \pm 0.034	-0.60 \pm 0.13	-0.15 \pm 0.090	-0.6 \pm 0.12
	γ 2S301W	-0.85 \pm 0.005	0.18 \pm 0.093	-0.51 \pm 0.088	-0.12 \pm 0.095
	Sum		0.1 \pm 0.18	-0.8 \pm 0.16	-0.3 \pm 0.18